Ran Frenkel
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Ran Frenkel
Karyopharm Therapeutics Inc. reported in an 8-K filed July 28, 2022 that Ran Frenkel resigned as Executive Vice President, Chief Development Officer, effective August 15, 2022. The proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $2,160,250 for Ran Frenkel in fiscal 2022, including a base salary of $279,375. Disclosed compensation is on record for 2 fiscal years.
“On July 26, 2022, Karyopharm Therapeutics Inc. (the "Company") and Ran Frenkel agreed that Mr. Frenkel will cease to serve as the Company's Executive Vice President, Chief Development Officer effective August 15, 2022.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Karyopharm Therapeutics Inc. (KPTI)
Proxy statement
Start not stated–2022-08-15
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Karyopharm Therapeutics Inc. (KPTI) | — | $279,375 | $2,160,250 |
| 2021 | Karyopharm Therapeutics Inc. (KPTI) | RPh. Executive Vice President, Chief Development Officer | $429,525 | $1,577,203 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.